OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
A Gene Panel Associated With Abemaciclib Utility in ESR1-Mutated Breast Cancer After Prior Cyclin-Dependent Kinase 4/6-Inhibitor Progression
Jamie O. Brett, Taronish D. Dubash, Gabriela N. Johnson, et al.
JCO Precision Oncology (2023), Iss. 7
Closed Access | Times Cited: 9
Jamie O. Brett, Taronish D. Dubash, Gabriela N. Johnson, et al.
JCO Precision Oncology (2023), Iss. 7
Closed Access | Times Cited: 9
Showing 9 citing articles:
Optimizing therapeutic approaches for HR+/HER2- advanced breast cancer: clinical perspectives on biomarkers and treatment strategies post-CDK4/6 inhibitor progression
J.M. Cejalvo Andujar, Francisco Ayala de la Peña, Mireia Margelí Vila, et al.
Cancer Drug Resistance (2025)
Open Access
J.M. Cejalvo Andujar, Francisco Ayala de la Peña, Mireia Margelí Vila, et al.
Cancer Drug Resistance (2025)
Open Access
CDK4/6 Inhibitor Efficacy in ESR1 -Mutant Metastatic Breast Cancer
Maxwell R. Lloyd, Jamie O. Brett, Ariel Carmeli, et al.
NEJM Evidence (2024) Vol. 3, Iss. 5
Closed Access | Times Cited: 4
Maxwell R. Lloyd, Jamie O. Brett, Ariel Carmeli, et al.
NEJM Evidence (2024) Vol. 3, Iss. 5
Closed Access | Times Cited: 4
Precision therapeutics and emerging strategies for HR-positive metastatic breast cancer
Maxwell R. Lloyd, Komal Jhaveri, Kevin Kalinsky, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 10, pp. 743-761
Closed Access | Times Cited: 4
Maxwell R. Lloyd, Komal Jhaveri, Kevin Kalinsky, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 10, pp. 743-761
Closed Access | Times Cited: 4
Modeling the novel SERD elacestrant in cultured fulvestrant-refractory HR-positive breast circulating tumor cells
Taronish D. Dubash, Aditya Bardia, Brian Chirn, et al.
Breast Cancer Research and Treatment (2023) Vol. 201, Iss. 1, pp. 43-56
Open Access | Times Cited: 4
Taronish D. Dubash, Aditya Bardia, Brian Chirn, et al.
Breast Cancer Research and Treatment (2023) Vol. 201, Iss. 1, pp. 43-56
Open Access | Times Cited: 4
Cracking the Genomic Code of CDK4/6 Inhibitor Resistance
Seth A. Wander, Aditya Bardia
Clinical Cancer Research (2024) Vol. 30, Iss. 10, pp. 2008-2010
Closed Access
Seth A. Wander, Aditya Bardia
Clinical Cancer Research (2024) Vol. 30, Iss. 10, pp. 2008-2010
Closed Access
The intersection of the HER2-low subtype with endocrine resistance: the role of interconnected signaling pathways
Gizem Yayli, Alexa Tokofsky, Utthara Nayar
Frontiers in Oncology (2024) Vol. 14
Open Access
Gizem Yayli, Alexa Tokofsky, Utthara Nayar
Frontiers in Oncology (2024) Vol. 14
Open Access
Efficacy of Subsequent Treatments After Disease Progression on CDK4/6 Inhibitors in Patients With Hormone Receptor–Positive Advanced Breast Cancer
Lis Victória Ravani, Pedro Calomeni, Maysa Vilbert, et al.
JCO Oncology Practice (2024)
Closed Access
Lis Victória Ravani, Pedro Calomeni, Maysa Vilbert, et al.
JCO Oncology Practice (2024)
Closed Access
Characterizing excision repair cross-complementing family genes as drug resistance biomarkers in breast cancer
Adam Hermawan, Herwandhani Putri
Beni-Suef University Journal of Basic and Applied Sciences (2023) Vol. 12, Iss. 1
Open Access | Times Cited: 1
Adam Hermawan, Herwandhani Putri
Beni-Suef University Journal of Basic and Applied Sciences (2023) Vol. 12, Iss. 1
Open Access | Times Cited: 1
Navigating next-generation HR+/HER2− metastatic breast cancer therapies: a critical commentary on abemaciclib vs. tucidinostat after palbociclib progression
Patrick Neven, Lieke Dullens, Sileny Han, et al.
Translational Breast Cancer Research (2023) Vol. 4, pp. 31-31
Open Access | Times Cited: 1
Patrick Neven, Lieke Dullens, Sileny Han, et al.
Translational Breast Cancer Research (2023) Vol. 4, pp. 31-31
Open Access | Times Cited: 1
